The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor α
Open accessAbstract
BACKGROUND: There are few effective treatments for ankylosing spondylitis, which causes substantial morbidity. Because of the central role of tumor necrosis factor alpha in the spondyloarthritides, we performed a randomized, double-blind, placebo-controlled trial of etanercept, a recombinant human tumor necrosis factor receptor (p75):Fc fusion protein, in patients with ankylosing spondylitis. METHODS: Forty patients with active, inflammatory ankylosing spondylitis were randomly assigned to receive twice-weekly subcutaneous injections of etanercept (25 mg) or placebo for four months. The primary end point was a composite of improvements in measures of morning stiffness, spinal pain, functioning, the patient's global assessment of disease activity, and joint swelling. Patients were allowed to continue taking nonsteroidal antiinflammatory drugs, oral corticosteriods (< or =10 mg per day), and disease-modifying antirheumatic drugs at stable doses during the trial. RESULTS: Treatment with etanercept resulted in significant and sustained improvement. At four months, 80 percent of the patients in the etanercept group had a treatment response, as compared with 30 percent of those in the placebo group (P=0.004). Improvements over base-line values for various measures of disease activity, including morning stiffness, spinal pain, functioning, quality of life, enthesitis, chest expansion, erythrocyte sedimentation rate, and C-reactive protein, were significantly greater in the etanercept group. Longitudinal analysis showed that the treatment response was rapid and did not diminish over time. Etanercept was well tolerated, with no significant differences in rates of adverse events between the two groups. CONCLUSIONS: Treatment with etanercept for four months resulted in rapid, significant, and sustained improvement in patients with ankylosing spondylitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Practical Nonparametric Statistics
Groggel, D. J. (2000) · Technometrics · doi:10.1080/00401706.2000.10486067 · Cited by 11,041
Krupp, L. B. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460115022 · Cited by 6,172
Evaluation of Diagnostic Criteria for Ankylosing Spondylitis
Linden, S. V. D., Valkenburg, H. A., & Cats, A. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270401 · Cited by 5,697
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
(2001) · Classic Papers in Rheumatology · doi:10.3109/9780203214237-70 · Cited by 1,833
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Cited by
Activators and Target Genes of Rel/NF-кB Transcription Factors: From Bench to Bedside
Loop, T., & Pahl, H. L. (2003) · Nuclear Factor кB · doi:10.1007/978-94-010-0163-2_1 · Cited by 3,169
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
TNF-mediated inflammatory disease
Bradley, Jr. (2008) · The Journal of Pathology · doi:10.1002/path.2287 · Cited by 2,094
“A randomized, double-blind trial of etanercept showed that treatment with etanercept for 4 months resulted in rapid, significant and sustained improvement in patients with ankylosing spondylitis [111].”
BackgroundMagro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Tumor Necrosis Factor-α Signaling in Macrophages
Parameswaran, N., & Patial, S. (2010) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v20.i2.10 · Cited by 1,437
Mann, D. L., McMurray, J. J. V., Packer, M., Swedberg, K., Borer, J. S., Colucci, W. S., Djian, J., Drexler, H., Feldman, A., Kober, L., et al. (2004) · Circulation · doi:10.1161/01.cir.0000124490.27666.b2 · Cited by 1,240
Van Assche, G., Dignass, A., Reinisch, W., van der Woude, C. J., Sturm, A., De Vos, M., Guslandi, M., Oldenburg, B., Dotan, I., Marteau, P., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.09.009 · Cited by 894
van der Heijde, D., Kivitz, A., Schiff, M. H., Sieper, J., Dijkmans, B. A. C., Braun, J., Dougados, M., Reveille, J. D., Wong, R. L., Kupper, H., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21913 · Cited by 872
Self-citationvan der Heijde, D., Dijkmans, B., Geusens, P., Sieper, J., DeWoody, K., Williamson, P., & Braun, J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20852 · Cited by 860
Adverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
Davis, J. C., Van Der Heijde, D., Braun, J., Dougados, M., Cush, J., Clegg, D. O., Kivitz, A., Fleischmann, R., Inman, R., Tsuji, W., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11325 · Cited by 754
Self-citationGardam, M. A., Keystone, E. C., Menzies, R., Manners, S., Skamene, E., Long, R., & Vinh, D. C. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00545-0 · Cited by 752
ASAS/EULAR recommendations for the management of ankylosing spondylitis
Zochling, J., van der Heijde, D., Burgos-Vargas, R., Collantes, E., Davis, J. C., Dijkmans, B., Dougados, M., Géher, P., Inman, R. D., Khan, M. A., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.041137 · Cited by 702
Self-citationUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
How to diagnose axial spondyloarthritis early
Rudwaleit, M., van der Heijde, D., Khan, M. A., Braun, J., & Sieper, J. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.011247 · Cited by 662
New Drugs for Rheumatoid Arthritis
Olsen, N. J., & Stein, C. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032906 · Cited by 626
Oxidative stress and left ventricular remodelling after myocardial infarction
Hori, M., & Nishida, K. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn335 · Cited by 523
Update on Spondyloarthropathies
Khan, M. A. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-12-200206180-00011 · Cited by 517
Rudwaleit, M., Khan, M. A., & Sieper, J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20990 · Cited by 515
Heijde, D. V. D., Landewé, R., Baraliakos, X., Houben, H., Tubergen, A. V., Williamson, P., Xu, W., Baker, D., Goldstein, N., & Braun, J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23901 · Cited by 514
Van Assche, G., Dignass, A., Bokemeyer, B., Danese, S., Gionchetti, P., Moser, G., Beaugerie, L., Gomollón, F., Häuser, W., Herrlinger, K., et al. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.005 · Cited by 463
Brandt, J., Khariouzov, A., Listing, J., Haibel, H., Sörensen, H., Grassnickel, L., Rudwaleit, M., Sieper, J., & Braun, J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11017 · Cited by 458
Rudwaleit, M., Listing, J., Brandt, J., Braun, J., & Sieper, J. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.016386 · Cited by 439
Optimizing anti-TNF treatment in inflammatory bowel disease
Rutgeerts, P., van Assche, G., & Vermeire, S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.070 · Cited by 429
Braun, J., Pham, T., Sieper, J., Davis, J., van der Linden, S., Dougados, M., & van der Heijde, D. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.9.817 · Cited by 425
Self-citationAnker, S. D., & Coats, A. J. S. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00470-9 · Cited by 367
Zochling, J. (2011) · Arthritis Care & Research · doi:10.1002/acr.20575 · Cited by 349
Mease, P. J. (2011) · Arthritis Care & Research · doi:10.1002/acr.20577 · Cited by 342
Boetticher, N. C., Peine, C. J., Kwo, P., Abrams, G. A., Patel, T., Aqel, B., Boardman, L., Gores, G. J., Harmsen, W. S., McClain, C. J., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.057 · Cited by 340
Fungal Infections Complicating Tumor Necrosis Factor α Blockade Therapy
Tsiodras, S., Samonis, G., Boumpas, D. T., & Kontoyiannis, D. P. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60839-2 · Cited by 331
Ko, J. M., Gottlieb, A. B., & Kerbleski, J. F. (2009) · Journal of Dermatological Treatment · doi:10.1080/09546630802441234 · Cited by 313
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis
Calin, A., Dijkmans, B. A. C., Emery, P., Hakala, M., Kalden, J., Leirisalo-Repo, M., Mola, E. M., Salvarani, C., Sanmartí, R., Sany, J., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.020875 · Cited by 311
Minozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., González-Lorenzo, M., Bastiampillai, A. J., Gabrielli, E. M., Lonati, A. C., Moja, L., Cinquini, M., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1240783 · Cited by 308
Sfikakis, P. P. (2010) · Current Directions in Autoimmunity · doi:10.1159/000289205 · Cited by 275
Ankylosing spondylitis and bowel disease
Rudwaleit, M., & Baeten, D. (2006) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2006.03.010 · Cited by 275
Mitoma, H., Horiuchi, T., Hatta, N., Tsukamoto, H., Harashima, S.-I., Kikuchi, Y., Otsuka, J., Okamura, S., Fujita, S., & Harada, M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.060 · Cited by 270
Cho, J. H., & Feldman, M. (2015) · Nature Medicine · doi:10.1038/nm.3897 · Cited by 260
Short- and long-term effects of IL-1 and TNF antagonists on periodontal wound healing
Zhang, X., Kohli, M., Zhou, Q., Graves, D. T., & Amar, S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3514 · Cited by 71
“One such fusion protein of the p75 sTNFR and the Fc portion of human IgG1 (etanercept) is now commercially available for treating rheumatoid arthritis (36), ankylosing spondylitis (37), and psoriasis (38).”
Background
Metadata
- Authors
- Gorman, J. D., Sack, K. E., & Davis, J. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-05-02
- Volume
- 346
- Issue
- 18
- Pages
- 1349-1356
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2018410379
- Cited by
- 704
- References
- 25
- FWCI
- 41.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.